 LYON, France and CAMBRIDGE, Mass. , Nov. 05, 2020 GLOBE NEWSWIRE -- ERYTECH Pharma Nasdaq Euronext: ERYP, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces that an abstract detailing results from the NOPHO spons o red Phase 2 trial of eryaspase in ALL patients, has been selected for oral presentation at the upcoming 62 nd American Society of Hematology ASH Annual Meeting being held virtually December 5-8. A second abstract detailing population pharmacokinetics of eryaspase in ALL or pancreatic adenocarcinoma patients has been accepted for a poster presentation at the meeting. 